sur BOIRON (EPA:BOI)
Reorganization and job cuts at Boiron in France
Laboratoires Boiron announces a reorganization of its activity in France, mainly affecting its common-name homeopathy segment. This measure follows the delisting of homeopathy by Health Insurance, which caused a drop in sales of more than 100 million euros in five years. Thus, volumes have been reduced by a third since 2020.
The project provides for the elimination of 145 positions, divided between the closure of four distribution establishments and seven preparatory ones, as well as the reduction of medical visit activity. At the same time, eight positions will be created for Homeopathy Development Managers.
To mitigate the social impact, Boiron is proposing support measures including voluntary departures and reassignments.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de BOIRON